Survodutide
Peptide therapy: benefits, side effects, cost and protocols
C192H289N47O61
Survodutide is an experimental dual glucagon/GLP-1 receptor agonist developed by Boehringer Ingelheim as a weight loss drug. Unlike other dual agonists, it is a glucagon analog rather than an oxyntomodulin analog.
Sources: FDA / PubMed / ClinicalTrials.gov View
Spec sheet
- FDA status
- Research Only Not currently approved for human use in the US. Available as a research compound. Not eligible for compounding.
- Evidence
- Strong Evidence
Mechanism
How Survodutide works
Dual agonist that combines GLP-1 appetite suppression with glucagon's fat-burning and hepatic effects.
Evidence
Key studies
86 papers on PubMed
- 01
Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial
- 02
Kosiborod MN, Platz E, Wharton S et al
JACC Heart Fail / Phase 3
- 03
Survodutide cardiovascular safety and efficacy in obesity with increased cardiovascular risk under investigation
- 04
Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2)
- 05
Wharton S, le Roux CW, Kosiborod MN et al
Obesity (Silver Spring) / Phase 3
Survodutide reduced body weight and achieved ≥5% weight loss in obesity with/without type 2 diabetes.
- 06
Survodutide reduced body weight and achieved ≥5% weight loss in obesity with/without type 2 diabetes
- 07
Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1)
- 08
le Roux CW, Wharton S, Bozkurt B et al
Diabetes Obes Metab / Diabetes Obes Metab / Phase 3
Phase 3 trial investigating survodutide for weight loss in obesity without type 2 diabetes.
- 09
Phase 3 trial investigating survodutide for weight loss in obesity without type 2 diabetes
- 10
Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial
Compound
Survodutide compound data
- Formula
- C192H289N47O61
- Mol. weight
- 4232 g/mol
- PubChem CID
- 171378821 ↗
- IUPAC
- 18-[[(1S)-4-[[2-[[(1S)-2-[[2-[[(1S)-2-[[2-[[2-[[(5S)-5-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[1-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]cyclobutanecarbonyl]amino]-5-oxo-pentanoyl]amino]acetyl]amino]-3-hydroxy-butanoyl]amino]-3-phenyl-propanoyl]amino]-3-hydroxy-butanoyl]amino]-3-hydroxy-propanoyl]amino]-3-carboxy-propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxy-propanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methyl-pentanoyl]amino]-3-carboxy-propanoyl]amino]-4-carboxy-butanoyl]amino]-5-guanidino-pentanoyl]amino]propanoyl]amino]propanoyl]amino]hexanoyl]amino]-3-carboxy-propanoyl]amino]-3-phenyl-propanoyl]amino]-3-methyl-pentanoyl]amino]-6-[[(1S)-2-[[(1S)-1-[[(1S)-1-[[(1S)-2-[[(1S)-2-amino-1-methyl-2-oxo-ethyl]amino]-1-(hydroxymethyl)-2-oxo-ethyl]carbamoyl]-3-carboxy-propyl]carbamoyl]-3-methyl-butyl]amino]-1-(1H-indol-3-ylmethyl)-2-oxo-ethyl]amino]-6-oxo-hexyl]amino]-2-oxo-ethyl]amino]-2-oxo-ethyl]amino]-1-(hydroxymethyl)-2-oxo-ethyl]amino]-2-oxo-ethyl]amino]-1-(hydroxymethyl)-2-oxo-ethyl]amino]-2-oxo-ethyl]amino]-1-carboxy-4-oxo-butyl]amino]-18-oxo-octadecanoic acid
FAQ
Survodutide questions
What is SURVODUTIDE?
Survodutide is a dual GLP-1 and glucagon receptor agonist being researched as a next-generation weight loss peptide with potential liver health benefits.
How does SURVODUTIDE work?
Dual agonist that combines GLP-1 appetite suppression with glucagon's fat-burning and hepatic effects.
Is SURVODUTIDE legal to buy?
SURVODUTIDE is sold as a research chemical for laboratory use only. It is not approved for human use by the FDA. Regulations vary by jurisdiction.
Where can I buy SURVODUTIDE?
SURVODUTIDE is available as a research compound from verified online vendors. Always verify third-party testing before purchasing.
What category does SURVODUTIDE belong to?
SURVODUTIDE is primarily classified as a weight loss & metabolic peptide. Peptides researched for their effects on weight management, fat metabolism, appetite regulation, and metabolic enhancement. This category includes GLP-1 agonists, dual/triple agonists, and other metabolic peptides.
What are the research benefits of SURVODUTIDE?
SURVODUTIDE has been studied for: Weight loss research, Dual mechanism, Liver health potential. GLP-1/glucagon dual agonist; emerging weight loss research.
News
Survodutide in the news
Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss - AJMC
AJMC / 4 months ago
Survodutide Demonstrates Meaningful Weight Loss in Adults Without T2D - Medical Professionals Reference
Medical Professionals Reference / 5 months ago
Once-weekly survodutide linked to drop in body weight in obesity - Medical Xpress
Medical Xpress / 4 months ago
ADA 2026: Survodutide Cuts Visceral Fat and Normalizes Liver Fat in MASLD. Here's What the Data Mean for Metabolic Risk - Pharmacy Times
Pharmacy Times / 4 months ago
Addressing the bigger picture in obesity and metabolic dysfunction-associated steatohepatitis - Boehringer Ingelheim
Boehringer Ingelheim / 6 months ago
News aggregated via Google News. Inclusion does not imply endorsement.
Considering Survodutide?
The 2-minute quiz matches you with licensed providers who offer it. A clinician decides if it fits.